☰

Rachelle R. Olsen, Ph.D. - Publications

Affiliations: 
2011 Harvard University, Cambridge, MA, United States 
Area:
Cell Biology
Tree Info Grants Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Olsen RR, Ireland AS, Kastner DW, Groves SM, Spainhower KB, Pozo K, Kelenis DP, Whitney CP, Guthrie MR, Wait SJ, Soltero D, Witt BL, Quaranta V, Johnson JE, Oliver TG. ASCL1 represses a SOX9 neural crest stem-like state in small cell lung cancer. Genes & Development. PMID 34016693 DOI: 10.1101/gad.348295.121  0.35
2020 Slavish PJ, Chi L, Yun MK, Tsurkan L, Martinez NE, Jonchere B, Chai SC, Connelly M, Waddell MB, Das S, Neale G, Li Z, Shadrick WR, Olsen RR, Freeman KW, et al. Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer. Cancer Research. PMID 32651255 DOI: 10.1158/0008-5472.Can-19-3934  0.344
2020 García-López J, Wallace K, Otero JH, Olsen R, Wang YD, Finkelstein D, Gudenas BL, Rehg JE, Northcott P, Davidoff AM, Freeman KW. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma. Cell Reports. 30: 454-464.e5. PMID 31940489 DOI: 10.1016/j.celrep.2019.12.048  0.33
2020 Wallace K, Garcia-Lopez J, Otero J, Olsen R, DeVaux C, King A, Davidoff A, Freeman K. Abstract B30: ARID1A is a haploinsufficient tumor suppressor for N-Myc transformation of neural crest cells Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-B30  0.494
2019 Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, et al. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications. 10: 3485. PMID 31375684 DOI: 10.1038/S41467-019-11371-X  0.349
2015 Olsen RR, Mary-Sinclair MN, Yin Z, Freeman KW. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism. Plos One. 10: e0116998. PMID 25615615 DOI: 10.1371/journal.pone.0116998  0.421
2012 Olsen RR, Chung I, Zetter BR. Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo. Amino Acids. 42: 549-58. PMID 21909979 DOI: 10.1007/S00726-011-1032-X  0.56
2011 Olsen RR, Zetter BR. Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Molecular Cancer Research : McR. 9: 1285-93. PMID 21849468 DOI: 10.1158/1541-7786.Mcr-11-0178  0.548
2011 Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 30: 4386-98. PMID 21552288 DOI: 10.1038/Onc.2011.148  0.501
2011 Olsen RR, Chung I, Zetter BR. Abstract 248: Control of prostate tumor growth and centriole amplification by antizyme and antizyme inhibitor Cancer Research. 71: 248-248. DOI: 10.1158/1538-7445.Am2011-248  0.437
2010 Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, Olsen RR, Waghorne C, Zetter BR. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 2503-8. PMID 20133800 DOI: 10.1073/Pnas.0910649107  0.528
Show low-probability matches.